[PDF] Top 20 Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis
Has 10000 "Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis" found on our website. Below are the top 20 most common "Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis".
Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis
... of the IL-12 family consisting of two subunits, EBV-induced gene 3 (EBI3) and ...role in murine tumor models, and in various types of human cancer such as colorectal, pancreatic, or ... Voir le document complet
13
CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma
... to the PASD1 peptides were present in 12 of the 15 patients whose tumors expressed PASD1 protein, three patients recognizing the PASD1 peptides lacked detectable PASD1 ...PASD1 ... Voir le document complet
9
Role of ETS1 in the transcriptional network of diffuse large B cell lymphoma of the activated B cell-like type
... ]. For functional annotation [ 25 ], microarray data were processed with regular gene set enrichment analysis while RNA-Seq data were processed with preranked GSEA (Gene Set Enrichment Analysis) on fold ... Voir le document complet
17
An alternative way to look at diffuse large B-cell lymphoma : the impact of frequent engagement of ReIB NF-κB subunit on cell survival and patient outcome
... mammals, the NF-κB family is composed of five members, RelA (p65), RelB, cRel (Rel), NF-κB1 (p50 and its precursor p105) and NF-κB2 (p52 and its precursor p100) [ 10 ...homo- and ... Voir le document complet
138
Cytolytic T-cell response to the PASD1 cancer testis antigenin patients with diffuse large B-cell lymphoma
... Summary The identification of immunogenic cancer testis antigens (CTAs) as immunotherapeutic targets represents one approach to improve treatment options for diffuse large B-cell ... Voir le document complet
12
Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies
... and outcome. In univariate analysis, we observed a significant difference in PFS with a 4-year estimated PFS of ...46.1–76.4%) and OS of 93% (CI: 74.7–98.2%) versus 70.7% (CI: 53.7–82.4%) ... Voir le document complet
8
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.
... 2). In a multivariate Cox model adjusted for the COO effect, 2 of the 16 candidate genes (APOBEC3G and RAB33A) remained significantly associated with ...adjusted for the ... Voir le document complet
23
Subcutaneous Rituximab-MiniCHOP compared with subcutaneous Rituximab-MiniCHOP plus Lenalidomide in diffuse large B-Cell lymphoma for patients age 80 years or older.
... of the two main molecular –defined subtypes, namely, germinal center B-cell –like (GCB) and activated B-cell –like (ABC) subtypes, differs according to patient ...increase ... Voir le document complet
12
A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival
... lies in applying evidence-based medicine to routine medical practice in small scale private centres or community ...hospitals. In 2009, a study among lymphoma patients showed that ... Voir le document complet
12
Induction of autophagy and autophagy-dependent apoptosis in diffuse large B-cell lymphoma by a new antimalarial artemisinin derivative, SM1044
... Introduction Diffuse large B- cell lymphoma (DLBCL) is a common aggressive malignancy of mature B cells, accounting for 30–40% of adult non- Hodgkin’s lymphoma ... Voir le document complet
18
Long non-coding RNAs as molecular signatures for canine B-Cell lymphoma characterization
... Background: Diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) and follicular lymphoma (FL) are the most common B-cell ... Voir le document complet
12
Gene expression-based risk score in diffuse large B-cell lymphoma.
... instability and apoptosis in tumor cells of patients within high risk GERS group (supplementary Figure S1 and supplementary Tables S1, S2 and ...S3). In particular, enrichment ... Voir le document complet
12
Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients
... Materials and Methods ...Subjects and Samples. Peripheral blood was obtained from 31 patients with B cell lymphoma attending the Haema- tology Departments of the John ... Voir le document complet
10
Primary high-grade B-cell central nervous system lymphoma in a patient with tumefactive multiple sclerosis treated with Natalizumab.
... 40-year-old patient with a 20 year history of “tumefactive” multiple sclerosis (MS) (Figure 1, 2007 and 2008) fulfilling the current diagnostic criteria, who had never benefited of any type of ... Voir le document complet
1
Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination
... Previously, the RhoA/ROCK/MLC transduction pathway has been identified as a mechanism for the STIM1-mediated contribution to thrombin-induced disruption of endothelial ...link the Ca 2+ ... Voir le document complet
18
Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase–positive anaplastic large cell lymphoma with tumor dissemination and relapse risk
... of the anti-ALK antibody response may serve as a surrogate marker for the degree of immune-mediated destruction of lymphoma cells in ALK-positive ...by the tumor and/or ... Voir le document complet
6
Migration Properties Distinguish Tumor Cells of Classical Hodgkin Lymphoma from Anaplastic Large Cell Lymphoma Cells
... Anaplastic large cell lymphoma (ALCL) and classical Hodgkin lymphoma (cHL) are lymphomas that contain CD30-expressing tumor cells and have numerous pathological ...disease. ... Voir le document complet
17
BMP7 Expression Correlates with Secondary Drug Resistance in Mantle Cell Lymphoma
... on the road to personalized medicine, where every patient is expected to gain access to personalized ...done in most (past and present) profiling studies performed on heterogeneous pathologies ... Voir le document complet
10
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non- Hodgkin lymphoma involves modulation of G2/M cell cycle arrest
... Conversely in Ramos, Rec-1, OCI- Ly8, and U2932 cells, CDK1 phosphorylation at Tyr15 and Thr14 remained high, whereas phosphorylation at Thr161 was low when measured in Ramos and Rec-1 ... Voir le document complet
15
Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets
... T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets Reliable information regarding the current prevalence of peripheral ... Voir le document complet
4
Sujets connexes